The impact of previous therapy on overall-survival in registration clinical trials for 1st line metastatic breast cancer a systemic review-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The impact of previous therapy on overall-survival in registration clinical trials for 1st line metastatic breast cancer a systemic review

Published:2024-10 Issue: Volume:202 Page:104455
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Remilah Areen Abu,Krayim Bilal,Amir Eitan,Tibau Ariadna,Robson Mark E.,Abuhadra Nour,Chen Yuan,Shepshelovich Daniel,Goldvaser Hadar^ORCID

Funder

Conquer Cancer Foundation

American Society of Clinical Oncology

Publisher

Elsevier BV

Reference53 articles.

1. Reporting of post-protocol therapies in metastatic breast cancer registration clinical trials: a systematic review;Shachar;Cancer Treat. Rev.,2024

2. Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival;Miglietta;ESMO Open,2022

3. ESMO Guidelines Committee. ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer;Gennari;Ann. Oncol.,2021

4. Rashmi Kumar N., Schonfeld R., Gradishar W.J., Lurie R.H., Moran M.S., Abraham J., et al. NCCN Guidelines Version 1.2024 Breast Cancer [Internet]. 2024. Available from: 〈https://www.nccn〉.

5. Biomarkers for systemic therapy in metastatic breast cancer: ASCO Guideline Update;Henry;J. Clin. Oncol.,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP